
    
      The TYSABRI Global Observational Program in Safety (TYGRIS) is a safety observational cohort
      program designed to obtain long-term safety data in multiple sclerosis (MS) participants
      treated with natalizumab in a clinical practice setting in the United States or Canada.
    
  